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A B S T R A C T
Mitochondrial reactive oxygen species (mtROS) generated continuously under physiological conditions have
recently emerged as critical players in the regulation of immune signaling pathways. In this study we have
investigated the regulation of antiviral signaling by increased mtROS production in plasmacytoid dendritic cells
(pDCs), which, as major producers of type I interferons (IFN), are the key coordinators of antiviral immunity.
The early phase of type I IFN production in pDCs is mediated by endosomal Toll-like receptors (TLRs), whereas
the late phase of IFN response can also be triggered by cytosolic retinoic acid-inducible gene-I (RIG-I), expression
of which is induced upon TLR stimulation. Therefore, pDCs provide an ideal model to study the impact of
elevated mtROS on the antiviral signaling pathways initiated by receptors with distinct subcellular localization.
We found that elevated level of mtROS alone did not change the phenotype and the baseline cytokine proﬁle of
resting pDCs. Nevertheless increased mtROS levels in pDCs lowered the TLR9-induced secretion of pro-in-
ﬂammatory mediators slightly, whereas reduced type I IFN production markedly via blocking phosphorylation of
interferon regulatory factor 7 (IRF7), the key transcription factor of the TLR9 signaling pathway. The TLR9-
induced expression of RIG-I in pDCs was also negatively regulated by enhanced mtROS production. On the
contrary, elevated mtROS signiﬁcantly augmented the RIG-I-stimulated expression of type I IFNs, as well as the
expression of mitochondrial antiviral-signaling (MAVS) protein and the phosphorylation of Akt and IRF3 that are
essential components of RIG-I signaling. Collectively, our data suggest that increased mtROS exert diverse im-
munoregulatory functions in pDCs both in the early and late phase of type I IFN responses depending on which
type of viral sensing pathway is stimulated.
1. Introduction
Under oxidative stress conditions the intracellular levels of reactive
oxygen species (ROS) are elevated that by damaging diﬀerent biological
targets such as proteins, lipids or DNA can lead to a variety of pathol-
ogies. Nevertheless, functioning as signaling molecules, endogenous
ROS can contribute to the maintenance of redox balance and thus to the
physiological functions of the cells [1]. Although multiple mechanisms
can generate ROS within the cells in vivo, the mitochondrial electron
transport chain is assumed to be the major source of endogenous ROS
[2]. In the respiratory chain electrons are passed through a series of
protein complexes (labeled Complex I–IV) via redox reactions. As a
natural process, some electrons leave the electron transport chain and
react with molecular oxygen leading to the formation of mitochondrial
ROS (mtROS), the natural byproducts of oxidative metabolism. Mi-
tochondrial ROS have two faces: on the one hand, they maintain a fa-
vorable redox balance [3], on the other hand, contribute to the pa-
thogenesis of various oxidative stress-related diseases (reviewed in [4]).
Mitochondrial Complexes I-III are the major sources of mtROS pro-
duction: Complexes I and II release mtROS into the matrix, whereas
Complex III can produce them both into the matrix and the inter-
membrane space of mitochondria [2,5]. Mitochondrial ROS can easily
penetrate from the intermembrane space to the cytosol and act as sig-
naling molecules via directly modifying the activity of cell-signaling
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components, thus inﬂuencing the outcome of signal transduction
pathways [6,7].
An extensive body of literature indicates the involvement of mtROS
in multiple signaling pathways (reviewed in [3]) including antiviral
responses (reviewed in [8]), which is in the focus of our present study.
However, the putative regulatory role of mtROS on signaling induced
by antiviral sensors of plasmacytoid dendritic cells (pDCs) has not been
investigated yet. Plasmacytoid DCs are the key regulators of antiviral
immunity and as professional type I interferon (IFN) producing cells,
they secrete 200–1000 times more type I IFNs than other leukocytes or
IFN-producing tissue cells (e.g. reactive epithelium) in response to
viruses [9]. The robust type I IFN production of pDCs is critical in the
clearance of certain acute viral infections as shown by the depletion of
pDCs that leads to impaired type I IFN secretion and persistence of viral
infection [10].
Viruses are very heterogeneous in structure, genomic composition,
and replication strategy; therefore, multiple sensors are required to
detect their presence in various cellular compartments. The initial re-
cognition of virus-derived nucleic acids and the ﬁrst wave of type I IFN
production are mainly mediated by endosomal Toll-like receptor (TLR)
7 and 9 in pDCs that are selectively expressed in these cells. In the early
phase of viral infection pDCs circulating in blood or locating in sec-
ondary lymphoid tissues engulf non-infectious viral particles or apop-
totic bodies from infected cells and produce high amount of type I IFNs
that is independent of intrinsic viral replication in pDCs [11]. Later on,
when pDCs leave the bloodstream and accumulate at the site of infec-
tion, they might become infected by viruses that requires the detection
of viral replication intermediates by cytosolic receptors such as retinoic
acid-inducible gene-I (RIG-I)-like helicases [12]. We have previously
demonstrated that in contrast with conventional dendritic cells and
macrophages [13], RIG-I is not expressed in resting pDCs, but it can be
upregulated by endosomal TLR stimulation [14]. Based on our results
we proposed a model where TLRs orchestrate the ﬁrst phase of type I
IFN production whereas RIG-I participates only in the late phase of
antiviral responses by boosting the production of type I IFNs in pDCs.
Based on the unique expression of the above mentioned viral sen-
sors in pDCs, we aimed to investigate the possible regulatory role of
mtROS on the antiviral signaling pathways initiated by receptors lo-
calized to diﬀerent cellular compartments. To this end, we studied the
potential impact of elevated mtROS levels on the early phase of type I
IFN production mediated by endosomal TLRs and on the late phase of
type I IFN secretion induced by the cytosolic RIG-I sensor in pDCs.
2. Materials and methods
2.1. Cell line
In most of our experiments we used the human plasmacytoid den-
dritic cell line GEN2.2 [49] (kindly provided by Dr. Joel Plumas and Dr.
Laurence Chaperot, Research and Development Laboratory, French
Blood Bank Rhône-Alpes, Grenoble, France), which is deposited with
the CNCM (French National Collection of Microorganism Cultures)
under the number CNCMI-2938. GEN2.2 cells were grown on a layer of
mitomycin C (Sigma-Aldrich, St. Louis, MO, USA)-treated murine MS5
feeder cells (Cat. no. ACC 441, Leibniz Institute DSMZ-German Col-
lection of Microorganisms and Cell Cultures, Braunschweig, Germany)
in RPMI 1640 medium (Sigma-Aldrich) supplemented with 10% heat-
inactivated FBS (Life Technologies Corporation, Carlsbad, CA, USA),
100 U/ml penicillin, 100 ng/ml streptomycin (both from Sigma-Al-
drich) and 5% non-essential amino acids (Life Technologies Corpora-
tion). For experiments, the GEN2.2 cells were removed from the feeder
layer and seeded on 24-well plates at a concentration of 5 × 105 cells/
500 μl in complete RPMI 1640 medium (Sigma-Aldrich). Cell lines were
grown and incubated at 37 °C in 5% CO2 humidiﬁed atmosphere.
2.2. Isolation and culturing of primary human pDCs
Primary pDCs were isolated from human heparinized leukocyte-
enriched buﬀy coats, which were obtained from healthy blood donors
drawn at the Regional Blood Center of Hungarian National Blood
Transfusion Service (Debrecen, Hungary) in accordance with the
written approval of the Director of the National Blood Transfusion
Service and the Regional and Institutional Ethics Committee of the
University of Debrecen, Faculty of Medicine (Debrecen, Hungary).
Peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll-
Paque (GE Healthcare, Uppsala, Sweden) density gradient centrifuga-
tion. Plasmacytoid DCs were then puriﬁed from PBMCs by positive
selection using the human CD304 (BDCA-4/Neuropilin-1) MicroBead
Kit (Miltenyi Biotec, Bergish Gladbach, Germany), according to the
manufacturer's protocol. After separation on VarioMACS magnet, the
purity of isolated pDCs was > 96% as conﬁrmed by ﬂow cytometry.
Freshly isolated pDCs were cultured in 48-well cell culture plates at
a density of 5 × 105 cells/ml in RPMI 1640 medium (Sigma-Aldrich)
supplemented with 10% heat-inactivated FBS (Life Technologies
Corporation), 2 mM L-glutamine, 100 U/ml penicillin, 100 ng/ml
streptomycin (all from Sigma-Aldrich), and 50 ng/ml recombinant
human IL-3 (Peprotech EC, London, UK). During treatments cells were
incubated at 37 °C in a humidiﬁed atmosphere containing 5% CO2.
2.3. Induction of elevated level of mtROS
To induce elevated mtROS generation, cells were treated with
Antimycin-A (AMA; Sigma-Aldrich). To detect mtROS production
GEN2.2 cells were stained with 5 µM MitoSox™ Red mitochondrial su-
peroxide indicator (Life Technologies Corporation) according to the
manufacturer's recommendations. The MitoSox™ Red loaded cells were
exposed to increasing concentrations of AMA (0.1, 0.2, 0.5, 1 and 2 µg/
ml; Sigma-Aldrich) for 6 h. In parallel experiments cells were also
treated with MitoTEMPO (300 µM, Sigma-Aldrich), a mitochondria-
targeted antioxidant, which is a speciﬁc scavenger of mtROS.
MitoTEMPO was added 1 h prior to or along with the AMA treatment.
Following treatments the ﬂuorescence intensity of MitoSox™ Red was
measured at 580 nm with FACS Calibur ﬂow cytometer (Becton
Dickinson, Franklin Lakes, NJ, USA) and data were analyzed by FlowJo
software (Treestar, Ashland, OR, USA). The viability of the AMA-ex-
posed cells was assessed by 7-aminoactinomycin-D (7-AAD; 10 µg/ml;
Sigma-Aldrich) staining using ﬂow cytometric analysis.
2.4. Cell stimulation
For activation, cells were exposed to the TLR9 agonist CpG-A (ODN
2216, 1 μM; Cat. no. HC4037 from Hycult Biotech, Uden, The
Netherlands) in the absence or presence of AMA (0.5 μg/ml; Sigma-
Aldrich) for 6 h. The optimal concentration of AMA was chosen based
on preliminary experiments performed on GEN2.2 cells.
To induce RIG-I expression, cells were incubated with 0.25 μM CpG-
A for 16 h. Thereafter cells were washed, re-seeded in fresh, complete
RPMI 1640 medium and stimulated with 5′ triphosphate-double
stranded RNA (5′ppp-dsRNA, Cat. no. tlrl-3prna from InvivoGen, San
Diego, CA, USA), a speciﬁc agonist of RIG-I, complexed with the
transfection reagent LyoVec™ (InvivoGen), according to the manu-
facturer's recommendations. Brieﬂy, 25 μl of the 5′ppp-dsRNA-LyoVec
complex containing 1 μg/ml working concentration of the RIG-I ligand
was added to the cells for the indicated time period in all experiments.
In parallel experiments cells were exposed to 0.5 μg/ml AMA (Sigma-
Aldrich) in combination with 5′ppp-dsRNA.
2.5. Flow cytometry
After 24 h of treatments the phenotypical analysis of the cells was
performed by ﬂow cytometry using FITC-labeled monoclonal antibodies
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against CD40 and CD80 (Cat. no. 334306 and 305206 both from
BioLegend, San Diego, CA, USA), PE-labeled CD86 (Cat. no. FAB141P
from R&D System, Minneapolis, MN, USA), HLA-DQ (Cat. no. 318106
from BioLegend) and isotype-matched control antibodies (all from
BioLegend). Fluorescence intensities were measured with FACS Calibur
(Becton Dickinson) and data were analyzed with FlowJo software
(TreeStar).
2.6. ELISA
Cell culture supernatants were harvested after 6 h of treatments and
the concentrations of TNF-α, IL-6 and IL-8 were measured with the BD
OptEIA human ELISA kits (BD Biosciences, San Diego, CA, USA). The
pre-coated human IFN-α ELISA kit was purchased from PBL
InterferonSource (Piscataway, NJ, USA). Assays were performed ac-
cording to the manufacturer's instructions. Absorbance measurements
were carried out by a Synergy HT microplate reader (Bio-Tek
Instruments, Winooski, VT, USA) at 450 nm.
2.7. Quantitative real time PCR
Total RNA was isolated from 5 × 105 cells using TRI reagent
(Molecular Research Center, Inc., Cincinnati, OH, USA). Total RNA
(1 μg) was treated with DNase I (Thermo Fisher Scientiﬁc, Waltham,
MA, USA) to exclude ampliﬁcation of genomic DNA then reverse
transcribed into cDNA using the High Capacity cDNA RT Kit of Applied
Biosystems (Carlsbad, CA, USA). The cDNA products were diluted at a
ratio of 1:2, then ampliﬁed using Dream Taq DNA Polymerase (Thermo
Fisher Scientiﬁc) and IFNA1 (Assay ID Hs. PT.49a.3184790.g,
Integrated DNA Technologies, Coralville, IA, USA) gene-speciﬁc assay
according to the manufacturer's instructions. Quantitative PCR was
performed using the ABI StepOne Real-Time PCR System (Applied
Biosystems) and cycle threshold values were determined using the
StepOne v2.1 Software (Applied Biosystems). The relative amount of
mRNA (2−ΔCt) was obtained by normalizing to the cyclophilin house
keeping gene in each experiment.
2.8. Western blotting
For Western blotting 5 × 105 cells were lysed in Laemmli buﬀer and
then the protein extracts were resolved by SDS-PAGE using 10% poly-
acrylamide gels and electro-transferred to nitrocellulose membranes
(Bio-Rad Laboratories GmbH, Munich, Germany). Non-speciﬁc binding
sites were blocked with 5% non-fat dry milk (or 5% BSA in case of
phospho-IRF3) diluted in TBS Tween buﬀer (50 mM Tris, 0.5 M NaCl,
0.05% Tween-20, pH 7.4). Membranes were probed with the following
primary antibodies: anti-RIG-I (Cat. no. 4520, Cell Signaling, Danvers,
MA, USA), anti-phospho-IRF7 (S477; Cat. No. 12390, Cell Signaling),
anti-IRF7 (Cat. no. 4920, Cell Signaling), anti-phospho-IRF3 (S386; Cat.
no. ab76493, Abcam, Cambridge, UK), anti-IRF3 (Cat. no. 4302, Cell
Signaling), anti-phospho-Akt (S473; Cat. no. AF887, R & D System),
anti-Akt1 (Cat. no. sc-5298, Santa Cruz Biotechnology, Heidelberg,
Germany), anti-mitochondrial antiviral-signaling (MAVS; Cat. no.
3993, Cell Signaling) and anti-beta-actin (Cat. no. sc-47778, Santa Cruz
Biotechnology). The bound primary antibodies were detected with anti-
mouse or anti-rabbit horseradish peroxidase-conjugated secondary an-
tibodies (GE Healthcare, Little Chalfont, Buckinghamshire, UK) at a
dilution of 1:10,000 and were visualized by the ECL system using
SuperSignal West Pico or Femto chemiluminescent substrates (Thermo
Scientiﬁc, Rockford, IL, USA) and X-ray ﬁlm exposure. Densitometric
analysis of immunoreactive bands was performed using the Kodak 1D
Image Analysis Software version 3.6 (Kodak Digital Science Imaging,
Eastman Kodak Company, New Haven, CT, USA). To ensure equal
protein loading after staining with phospho-IRF7, phospho-IRF3 and
phospho-Akt speciﬁc antibodies the membranes were stripped and re-
probed with anti-IRF7, anti-IRF3 and anti-Akt1 antibodies, respectively.
Beta-actin served as loading control for RIG-I and MAVS.
2.9. Statistical analysis
Data from the diﬀerent treatment groups were analyzed by Student's
unpaired t-test or ANOVA, followed by Bonferroni post hoc analyses for
least-signiﬁcant diﬀerences. Data analysis was performed with
GraphPad Prism v.6. software (GraphPad Software Inc., La Jolla, CA,
USA). Diﬀerences were considered to be statistically signiﬁcant at p <
0.05.
3. Results
3.1. AMA treatment increases mtROS production in GEN2.2 cells that can
be prevented by pre-treatment with the antioxidant MitoTEMPO
The availability of human pDCs is limited due to their low frequency
in peripheral blood [9]. To overcome this limitation, in most of our
experiments we have used the human plasmacytoid dendritic cell line
GEN2.2, which is functionally similar to primary pDCs [15]. In the ﬁrst
step we have investigated the sensitivity of GEN2.2 cells to AMA, an
inhibitor of mitochondrial electron transport chain that we used to
increase mtROS generation in the cells. AMA binding to the quinone
reduction site of the cytochrome bc1 Complex (Complex III) inhibits the
transfer of electrons and subsequently leads to the release of ROS into
the mitochondrial matrix and to the intermembrane space [5]. First we
have determined the optimal concentration of AMA that increases the
level of mtROS consistently without aﬀecting cell viability. To this end,
GEN2.2 cells were loaded with MitoSox™ Red mitochondrial superoxide
indicator and then exposed to increasing concentration of AMA (as
described in Materials and Methods) for 6 h. Although, the intensity of
MitoSox™ Red ﬂuorescence increased in a dose dependent-manner, we
observed a signiﬁcant decrease in cell viability when reaching the AMA
concentration of 1 μg/ml (data not shown). However, exposure to
0.5 µg/ml of AMA resulted in a substantial and consistent increase in
MitoSox™ Red ﬂuorescence intensity (Fig. 1A, B), while did not aﬀect
cell viability assessed by 7-AAD staining (Fig. 1C). Thus, to mimic the
elevated production of mtROS in GEN2.2 cells induced by metabolic
changes or diﬀerent stress signals under in vivo conditions AMA was
used at 0.5 µg/ml concentration in all our further experiments.
To verify that the increased ﬂuorescence intensity of MitoSox™ Red
was due to the AMA-induced mtROS production we have repeated our
measurements in the presence of the mitochondria-targeted antioxidant
MitoTEMPO [16]. Pre-treatment of cells with MitoTEMPO and its par-
allel administration with AMA almost completely abolished the AMA-
induced mtROS generation in GEN2.2 cells. These results indicate that
the increased MitoSox™ Red ﬂuorescence was indeed due to mtROS
production triggered by the inhibition of Complex III activity and not to
other factors (Fig. 1A, B).
3.2. Increased levels of mtROS do not alter signiﬁcantly the CpG-A-induced
phenotypical changes of GEN2.2 cells but diminish their pro-inﬂammatory
cytokine and chemokine release
In the next step we investigated the eﬀects of elevated mtROS
production on the phenotype and pro-inﬂammatory cytokine and che-
mokine secretion of pDCs treated with CpG-A, a synthetic oligonu-
cleotide with unmethylated CpG motifs mimicking viral DNA [17]. This
type of CpG oligonucleotides is a potent activator of TLR9 and can re-
sult in robust type I IFN production in pDCs [18]. Non-activated and
CpG-A-activated pDCs were exposed to AMA and changes in the ex-
pression of cell surface markers were monitored by ﬂow cytometry,
whereas the amount of secreted IL-6, TNF-alpha and IL-8 proteins in the
cell culture supernatants was measured by ELISA. Speciﬁcally, we in-
vestigated the expression of the CD40, CD80 and CD86 costimulatory
molecules and the MHC class II family protein HLA-DQ that represents
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the activation and subsequent maturation of dendritic cells [19]. Our
results show that the AMA-induced production of mtROS does not aﬀect
cell surface expression of the above mentioned molecules indicating
that the elevated level of mtROS alone does not lead to the activation
and the maturation of pDCs (Fig. 2A–D). Nevertheless, co-stimulation of
pDCs with AMA and the TLR9 agonist CpG-A, which signiﬁcantly in-
creases the cell surface expression of all examined molecules when
applied alone, resulted in a moderate but not signiﬁcant decrease in the
expression of CD40, CD86 and HLA-DQ (Fig. 2A, C, D), whereas did not
aﬀect the expression of CD80 (Fig. 2B). Treatment of the GEN2.2 cells
with AMA alone does not aﬀect their basal cytokine and chemokine
secretion, whereas it decreases signiﬁcantly the TLR9-ligand induced
production of TNF-alpha and IL-8 (Fig. 3B, C). In levels of IL-6 we could
not observe signiﬁcant changes upon AMA treatment of TLR9-stimu-
lated cells (Fig. 3A). Based on our data, elevated production of mtROS
tends to inhibit TLR9-induced activation of pDCs and its eﬀects are
more apparent on cytokine and chemokine release than on phenotypic
changes.
3.3. Mitochondrial ROS suppress the CpG-A-induced production of IFN-α
via blocking IRF7 phosphorylation in GEN2.2 cells
The unique capability of pDCs is the massive production of type I
IFNs in response to a wide range of viruses [9]. Therefore, in our next
experiments we aimed to reveal the impact of elevated mtROS levels on
type I IFN production of pDCs. Previously we have described that the
type I IFN production of pDCs occurs in two waves. Endosomal TLRs
mediate the initial activation of the cells, whereas cytosolic RIG-I re-
ceptors induced by TLR activation can be engaged in the second wave
of type I IFN responses [14]. First we investigated how increased
mtROS aﬀect the initial wave of type I IFN production induced by
endosomal TLR activation. Resting or TLR9-stimulated GEN2.2 cells
were treated with AMA and 6 h after stimulation the expression of
IFNA1 gene and the production of IFN-α were measured. We found that
administration of AMA does not aﬀect the baseline expression of type I
IFN genes (Fig. 4A), and we could not detect IFN-α production in either
unstimulated or in AMA-treated cell (Fig. 4B), indicating that the ele-
vated level of mtROS alone does not induce type I IFN production of
pDCs. However, the CpG-A-induced expression of type I IFNs was sig-
niﬁcantly decreased at both mRNA and protein levels when cells were
activated in the presence of AMA (Fig. 4A, B).
Activation of the endosomal TLR9 receptor leads to the phosphor-
ylation of the IRF7 transcription factor through the MyD88-dependent
signaling pathway resulting in the production of type I IFNs [20]. To
analyze the molecular mechanism of the observed inhibitory eﬀects of
elevated mtROS on TLR9-mediated signal transduction, we have in-
vestigated the impact of AMA treatment on the activity of IRF7. We
have found that AMA alone does not alter the phosphorylation of IRF7
in resting cells, whereas it decreases this process in TLR9-stimulated
pDCs (Fig. 4C, D). Our data indicate that the negative regulatory eﬀect
of mtROS on the phosphorylation of IRF7 in the TLR9 signaling
pathway may be responsible for the diminished production of type I
IFNs in pDCs.
3.4. Elevated mtROS level decreases the CpG-A induced expression of RIG-I
The second wave of type I IFN responses can be mediated by cyto-
solic RIG-like helicases only after their expression is upregulated by
endosomal TLR activation in pDCs [14]. To investigate the eﬀect of
elevated mtROS level on RIG-I-mediated type I IFN production of pDCs,
ﬁrst, we have determined the lowest concentration of CpG-A which still
provides a robust induction of RIG-I in GEN2.2 cells. Based on our dose-
Fig. 1. Generation of elevated level of mtROS in GEN2.2 cells without aﬀecting the cell viability. Cells were loaded with MitoSox™ Red mitochondrial superoxide indicator and
then treated with AMA (0.5 μg/ml) for 6 h to increase the production of mtROS. As a control AMA was used in combination with MitoTEMPO (300 μM) that limits mtROS accumulation.
MitoTEMPO was added 1 h prior to and along with the AMA treatments. The ﬂuorescence intensity of MitoSox™ Red dye correlates with the level of mtROS generated in the cells. The
changes in ﬂuorescence intensities of MitoSox™ Red dye were monitored by ﬂow cytometry. A representative histogram (A) and the means ± SD (B) of eight independent experiments are
shown. The percentage of dead cells was determined by 7-AAD staining. (C) Dot plots are representatives of eight independent experiments. ****p < 0.0001 vs. control, ####p < 0.0001
vs. AMA. AMA: Antimycin-A.
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response curve obtained by using Western blot, we have found that
0.25 μM concentration of CpG-A can boost the expression of RIG-I
(Fig. 5A, B). Signiﬁcant RIG-I expression was induced after 16 h of
stimulation with CpG-A that was only slightly further increased by 24 h
(Fig. 5C, D). Therefore, to induce RIG-I expression GEN2.2 cell were
treated with 0.25 μM of CpG-A for 16 h in our subsequent experiments.
Next, we have studied the eﬀect of elevated mtROS levels on the
TLR9-induced expression of RIG-I. We have found that RIG-I is not
expressed in untreated or AMA-treated cells; however, the presence of
AMA interfered with the TLR9-induced expression of RIG-I signiﬁcantly
(Fig. 5E, F). These data together suggest that elevated levels of mtROS
inhibit both the early wave of type I IFN responses and the endosomal
TLR-induced expression of RIG-I in pDCs.
3.5. Increased level of mtROS enhances type I IFN production in RIG-I-
activated GEN2.2 cells whereas decreases it in CpG-A re-stimulated cells
Next we analyzed how the elevated level of mtROS might inﬂuence
the second wave of type I IFN production triggered by RIG-I. As we have
shown previously resting primary pDCs [14] as well as resting GEN2.2
cells (Fig. 5A–F) do not express RIG-I at the protein level. Therefore, we
provoked the upregulation of RIG-I in GEN2.2 cells using the TLR9 li-
gand CpG-A as described previously (Fig. 5A–D). After 16 h of stimu-
lation the cell supernatants were removed and after thorough washing
steps the cells were harvested and re-seeded in fresh medium as
described in the Materials and Methods. After treatment of pDCs with
5′ppp-dsRNA, a synthetic RIG-I ligand, which mimics replicating viral
RNA intermediates, type I IFN production was determined by Q-PCR
and Western blotting.
We have found that GEN2.2 cells are able to response to 5′ppp-
dsRNA treatment and produce type I IFNs when pre-activated by TLR9
ligand (Fig. 6A, B). These data imply that similar to primary pDCs,
TLR9-mediated signals induce the expression of functional RIG-I in
GEN2.2 cells. Interestingly, addition of AMA together with 5′ppp-
dsRNA, the speciﬁc RIG-I-ligand, augmented the RIG-I-elicited type I
IFN production (Fig. 6A, B). These data demonstrate that the endosomal
TLR-mediated early phase is inhibited (Fig. 4A, B), whereas the RIG-I-
mediated late phase of type I IFN production is intensiﬁed by the ele-
vated mtROS levels.
To exclude the possibility that the opposing regulatory eﬀects of
increased mtROS on TLR9- and RIG-I-mediated cellular responses are
due to the diﬀerent activation state of pDCs at the time of mtROS in-
duction, in parallel experiments, GEN2.2 cells were activated with a
small dose of CpG-A (0.25 µM) then re-stimulated with a higher dose of
CpG-A (1 µM) in the presence or absence of AMA (Fig. 6C, D). A ne-
gative regulatory role of elevated mtROS on type I IFN production was
also found when pDCs were re-stimulated by endosomal TLR ligand and
not by RIG-I-speciﬁc ligand (Fig. 6C, D). These observations suggest
that regulatory eﬀects of increased mtROS on type I IFN responses of
pDCs are signaling pathway speciﬁc but are independent of the
Fig. 2. Phenotypical analysis of AMA-exposed GEN2.2 cells. Cells were treated with AMA (0.5 μg/ml) and CpG-A (1 μM) separately and in combination or were left untreated.
Following 6 h of stimulation the expression levels of CD40 (A), CD80 (B), CD86 (C) and HLA-DQ (D) cell surface proteins were analyzed by ﬂow cytometry. Relative ﬂuorescence intensity
values were calculated using the respective isotype-matched control antibodies. The bars represent fold changes compared to the untreated control and data are expressed as the mean ±
SD of four independent experiments. *p < 0.05 vs. control. AMA: Antimycin-A.
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activation state of the cells.
3.6. Elevated level of mtROS has similar eﬀects on the ﬁrst and second wave
of type I IFN responses in primary human pDCs as in GEN2.2 cells
To validate the opposing modulatory role of mtROS in the regula-
tion of type I IFN production by pDCs, we isolated primary human pDCs
from peripheral blood of healthy donors and performed the same ex-
periments as on GEN2.2 cells. We found that similarly to GEN2.2 cells,
AMA treatment signiﬁcantly inhibited the TLR9-induced IFN-α pro-
duction (Fig. 7A, B), whereas signiﬁcantly increased the RIG-I-initiated
IFN-α secretion in primary human pDCs (Fig. 7C, D). These results
further support our observations that mtROS have a versatile regulatory
function in the coordination of the early and late phase of type I IFN
responses in human pDCs.
3.7. Increased level of mtROS positively regulates the expression and the
phosphorylation of the key signaling molecules of the RIG-I signaling cascade
In the last set of experiments, we have investigated the expression
level and the phosphorylation state of the key signaling components in
the RIG-I pathway to assess their relation to the positive regulatory role
of enhanced mtROS production.
RIG-I expression in GEN2.2 cells was induced as described above
and then cells were activated with 5′ppp-dsRNA in the presence or
absence of AMA. Following treatments, we have analyzed the expres-
sion of MAVS (also known as IPS-1 or Cardif) adaptor protein, and the
phosphorylation of IRF3 in cell lysates by Western blotting. MAVS
protein level was similar in control and 5′ppp-dsRNA stimulated cells;
however, it was increased signiﬁcantly by co-treatment with 5′ppp-
dsRNA and AMA (Fig. 8A, B). Furthermore, we have also found that the
RIG-I-induced IRF3 phosphorylation was signiﬁcantly higher upon co-
treatment of pDCs with RIG-I ligand and AMA compared to treatment
with 5′ppp-dsRNA only (Fig. 8C, D).
Previous publications have revealed that the phosphatidylinositol-3-
kinase (PI3K)/Akt signaling pathway is upregulated upon viral infec-
tion and required for the complete activation and phosphorylation of
IRF3 [21]. Furthermore, activation of PI3K/Akt signaling has already
been shown to be regulated in a redox-sensitive manner [22]. Based on
these observations we have analyzed the activation of Akt in the pre-
sence of elevated mtROS levels. Our data demonstrate that stimulation
of pDCs with 5′ppp-dsRNA tends to increase the phosphorylation of Akt;
however, the changes are not signiﬁcant compared to the control
(Fig. 8E, F). Nevertheless, co-exposure of the cells to 5′ppp-dsRNA and
AMA resulted in a signiﬁcant increase in Akt phosphorylation compared
both to the control and to the cells stimulated with 5′ppp-dsRNA only
(Fig. 8E, F). Based on our results enhanced mtROS level exerts a direct,
activating eﬀect on RIG-I signaling and contributes to the RIG-I induced
type I IFN production of pDCs.
Fig. 3. Pro-inﬂammatory cytokine and chemokine secretion of GEN2.2 cells exposed to AMA. Cells were stimulated with AMA (0.5 μg/ml) and CpG-A (1 μM) separately and in
combination. After 6 h cell culture supernatants were collected and the levels of IL-6 (A), TNF-alpha (B) and IL-8 (C) proteins were assessed by ELISA. Data are presented as means ± SD
of four independent experiments. *p < 0.05, **p < 0.01, ****p < 0.0001 vs. control, #p < 0.05, ###p < 0.001 vs. CpG-A. AMA: Antimycin-A.
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4. Discussion
Mitochondria-derived ROS are continuously generated under
normal conditions and at physiological levels they function as second
messengers in a broad range of signaling pathways, thus exert bene-
ﬁcial eﬀects on several cellular processes [4]. Nevertheless, the in-
creased production of mtROS has been associated with multiple
pathologies such as cancer, hypertension, atherosclerosis, diabetes,
autoimmune disorders [4] or age-related diseases [23]. Over the past
decades a myriad of studies also demonstrated the critical role of
mtROS in cellular signaling pathways and innate immune responses
including antiviral and antibacterial immunity [24–26]. In this study
we aimed to characterize the role of mtROS in the TLR- and RIG-I-
mediated type I IFN responses in human pDCs that play a pivotal role in
antiviral immunity.
Various exogenous and endogenous stimuli, including im-
munoreceptor ligation, cytokine stimulation, hypoxia and infections
can increase mtROS levels. Besides other pathogens, a number of
viruses cause oxidative stress to the host cells to manipulate signaling
pathways and promote their replication [27–29]. Infections by blood-
borne hepatitis viruses, human immunodeﬁciency virus, inﬂuenza A,
Epstein-Barr virus, respiratory syncytial virus, and other viruses can
increase ROS production or decrease cytosolic antioxidant levels (re-
viewed in [30]). Increased ROS production might contribute to al-
terations in mitochondrial functions and dysfunctional mitochondria, in
turn, can contribute to exacerbate oxidative stress [31]. Furthermore,
certain viral proteins are able to directly [32] or indirectly [33] trigger
enhanced release of ROS from mitochondria. Not only replication of
viruses in the host cells but also sensing of viral components and da-
mage-associated molecular pattern (DAMP) molecules by immune cells
via pattern recognition receptors can boost mtROS generation. It has
been demonstrated that stimulation of cell surface TLRs (TLR1, TLR2
and TLR4) but not of endosomal TLRs (TLR3, TLR7, TLR8 and TLR9)
resulted in increased mtROS production through TNF-receptor asso-
ciated factor 6 (TRAF6) and evolutionarily conserved signaling inter-
mediate in Toll pathway (ECSIT) signaling [34]. When TRAF6 and
ECSIT were depleted, macrophages produced signiﬁcantly less mtROS
that resulted in decreased bactericidal activity [34]. Plasmacytoid DCs
are considered to be a unique dendritic cell subset that exhibit a distinct
TLR repertoire and rely mainly on the endosomal TLR7 and TLR9 re-
ceptors to sense viral infections. However, recent studies have reported
that pDCs from healthy subjects also express TLR2 on the cell surface
[35,36], which recognizes a wide array of viral proteins after forming
heterodimers with TLR1 or TLR6 [37]. Virus-infected cells release high
mobility group box 1 (HMGB1), which functions as an extracellular
signaling and DAMP molecule [38]. It has been shown that HMGB1
binds to at least ﬁve diﬀerent cell surface receptors including receptor
for advanced glycation endproducts (RAGE) [39] expressed by pDCs
[40]. Ligand-RAGE interaction generates oxidative stress via activation
of NADPH oxidase and ampliﬁcation of mtROS production (reviewed in
[41]). These ﬁndings indicate that several mechanisms can be re-
sponsible for enhanced mtROS production in pDCs at the early phase of
Fig. 4. Eﬀects of AMA on the production of type I IFNs and phosphorylation of IRF7 in TLR9-activated GEN2.2 cells. Cells were stimulated with the TLR9 agonist CpG-A (1 μM) in
the presence or absence of AMA (0.5 μg/ml). After 6 h of stimulation the mRNA expression of IFNA1 was measured by real-time PCR (A). The level of secreted IFN-α cytokine was
determined by ELISA (B). Cells were stimulated for 30 min as described above then the levels of the phosphorylated (p-IRF7) and native form of IRF7 were determined by Western blotting
(C, D). Bars represent the means ± SD of three individual experiments (A, B, D) and a representative blot is shown (C). ***p < 0.001, ****p < 0.0001 vs. control, #p < 0.05, ##p < 0.01,
####p < 0.0001 vs. CpG-A. AMA: Antimycin-A, ND: not determined.
Z. Agod et al. Redox Biology 13 (2017) 633–645
639
viral infection.
Previously, we have shown that exogenously added ROS impact the
cellular responses of primary human pDCs to microbial stimulus. Most
importantly, a low dose of hydrogen peroxide (H2O2) inhibited the
TLR7-induced phenotypic activation, cytokine production, and the T-
cell-activating capacity of pDCs [42]. Our recent results show that si-
milarly to H2O2, mtROS decrease the TLR9-induced type I IFN secretion
of both GEN2.2 cells and primary pDCs. Thus, our results suggest that
endosomal TLR-mediated antiviral responses of human pDCs are
greatly sensitive to ROS and reduced when exposed to either exogenous
or endogenous sources of ROS.
Previously, it was thought that plasmacytoid DCs preferentially use
the TLR system rather than RIG-I-like receptors (RLR) for the detection
of viral infections contrary to conventional dendritic cells or
Fig. 5. Dose- and time-dependent induction of cytosolic RIG-I receptor in GEN2.2 cells and the expression of RIG-I in AMA-exposed cells. In order to induce the cytosolic
expression of RIG-I GEN2.2 cells were treated with increasing concentration of the speciﬁc TLR9 ligand, CpG-A (ranging from 0.01 to 0.5 μM). After 16 h the presence of RIG-I was
detected in the cell lysates by Western blotting (A, B). To evaluate the time-dependent induction of RIG-I, GEN2.2 cells were exposed to 0.25 μM of CpG-A then the expression of RIG-I was
measured in diﬀerent time points (C, D). Finally cells were exposed to 0.25 μM of CpG-A in the presence or absence of AMA (0.5 μg/ml) or left untreated, for 16 h. Then cells were lysed
and the protein level of RIG-I was assessed (E, F). Representative blots (A, C, E) and the means ± SD of four independent experiments (B, D, F) are shown. ***p < 0.001, ****p < 0.0001
vs. controls, ###p < 0.001 vs. CpG-A. AMA: Antimycin-A, ND: not determined.
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macrophages [43]. However, we have recently found that RIG-I also
contributes to viral recognition and subsequent antiviral immune re-
sponses of pDCs [14]. In resting human pDCs, RIG-I is expressed at a
very low level, but its expression is greatly upregulated by stimulating
the cells with TLR7 or TLR9 ligands [14]. Thus, our previous results
imply that upon recognition of viral nucleic acids the early type I IFN
response depends on TLR-mediated signals, whereas the second wave of
type I IFN production can be mediated by RLR signaling as well. After
sensing viral nucleic acids, TLR7 and TLR9 receptors activate NF-κB and
IRF7 in a MyD88-dependent manner, whereas RLRs interact with the
MAVS adaptor protein leading to activation of the NF-κB, IRF3 and
IRF7 transcription factors [44]. Similar to TLRs, the signaling of cyto-
solic RLRs is also regulated via mtROS. This was explored by the use of
autophagy defective Atg5-/- mouse ﬁbroblasts and macrophages, which
accumulate dysfunctional mitochondria as well as mitochondria-asso-
ciated MAVS and exhibit elevated mtROS levels [45]. Atg5-/- cells also
possess increased RLR signaling, type I IFN secretion and resistance to
vesicular stomatitis virus (VSV) infection that can be blocked by anti-
oxidant treatment [45]. Our current ﬁndings that mtROS have a posi-
tive impact on the TLR-induced RIG-I pathway in pDCs, are in line with
these previous results showing that mtROS potentiate RLR signaling
[45]. Thus, our results further support the idea that mtROS are im-
portant second messengers in the RIG-I-MAVS signaling pathway
during viral infection. A recent study concluded that mtROS modulate
the DNA virus-triggered but not the RNA virus-initiated innate immune
responses negatively in a murine model [46]. Inhibition of electron
transport chain decreased the Herpes simplex virus (HSV)- but not the
Sendai virus-induced production of cytokines indicating that mi-
tochondrial oxidative stress modulates DNA-driven innate immune re-
sponses, whereas RIG-I, which recognizes Sendai virus is insensitive to
mtROS [46]. In addition, murine peritoneal macrophages treated with
AMA showed diminished CCL5 and IFN-β production upon stimulation
of TLR2, TLR4, TLR9 and DNA receptors but not of RLRs [24]. More-
over, pre-treatment with inhibitors of the electron transport chain re-
duced the HSV-2-induced IκBα phosphorylation and IRF3 nuclear
translocation in human THP1 macrophages and murine peritoneal cells.
By contrast, our ﬁndings demonstrate increased IRF3 activation upon
AMA treatment of RIG-I-stimulated pDCs and we suppose that the
varying results might be explained by cell type speciﬁcities. Since RIG-I
might also signal through IRF7 we have also measured its phosphor-
ylation at serine 477 following treatments; however, we could not de-
tect any diﬀerences (data not shown). Therefore, we suggest that
mtROS promote the RIG-mediated type I IFN production through en-
hancing the activation of IRF3 in human pDCs.
Despite the identiﬁcation of many signaling partners linking MAVS
to the IRF and NF-κB routes the regulating mechanisms of MAVS in
virus-induced signaling are poorly understood. A recent study revealed
that PI3K and Akt play a pivotal role for the RIG-I mediated signaling
Fig. 6. RIG-I and TLR9 induced type I IFN production in CpG-A-pre-conditioned GEN2.2 cells in the presence of AMA. Cells were pre-treated with CpG-A (0.25 μM) for 16 h to
induce the cytosolic expression of RIG-I. Following thorough washing steps cells were re-exposed to the speciﬁc RIG-I ligand 5′ppp-dsRNA (RIGL, 1 μg/ml) in the presence or absence of
AMA (0.5 μg/ml). The IFNA1 mRNA expression level was determined by real-time PCR after 3 h (A) and IFN-α protein level was assessed by ELISA after 6 h (B). In parallel experiments
the re-activation of the cells was carried out with high dose of CpG-A (1 μM) in combination or not with AMA (0.5 μg/ml). IFNA1 mRNA (C) and IFN-α protein levels (D) were measured
as in (A) and (B), respectively. Data are presented as means ± SD of four individual experiments. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 vs. control, #p < 0.05 vs. RIGL
and ##p < 0.01 vs. CpG-A. AMA: Antimycin-A, ND: not determined.
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via association with MAVS [21]. Inhibition of PI3K and Akt blocked
IRF3 activation and IFN-β expression induced by the RIG-I agonist short
polyinosinic-polycytidylic acid (polyI:C) or Sendai virus in macro-
phages. Further, it was shown that the pleckstrin homology domain of
Akt interacts with the CARD domain of MAVS and the regulatory unit of
PI3K also associates with it. These results suggest that Akt and MAVS
provide a signaling platform for activating downstream signaling
pathways upon viral infection. Moreover, a recent study indicates that
the release of mtROS into the cytoplasm induces ROS-dependent
phosphorylation of Akt [47]. In line with these reported ﬁndings we
observed that RIG-I stimulation is associated with the augmentation of
Akt phosphorylation, that could be further increased by AMA treat-
ment. When investigating MAVS protein levels we could detect an
mtROS-dependent but RIG-I-independent upregulation of the protein
level. These observations correlate with previous ﬁndings showing that
oxidative-stress can lead to MAVS oligomerization and subsequent ac-
tivation independently of RIG-I helicases [48]. Based on these ﬁndings
we suggest that one of the mechanisms whereby mtROS support the
RIG-I mediated signaling pathway is the modulation of MAVS activity,
however, this hypothesis requires further clariﬁcation.
Plasmacytoid DCs are the major sources of type I IFNs upon viral
infections; however, the excessive production of type I IFNs is not al-
ways beneﬁcial, as it can result in uncontrolled inﬂammation and de-
struction of healthy tissues [43]. In this regard, control of the TLR-
mediated systemic IFN responses by circulating pDCs during the early
phase of viral infection may prevent excessive tissue damage. At the
late stages of infection pDCs redistribute to the infected peripheral
tissues where they can be exposed to elevated levels of ROS produced
by inﬂammatory cells (reviewed in [26]) and can be infected by re-
plicating viruses leading to cytosolic recognition of viral RNA by RIG-I,
which results in the second wave of type I IFN production in pDCs. Of
note, the RIG-I mediated second phase of IFN production is much lower
compared to the TLR-initiated ﬁrst phase of IFN secretion and is
boosted by mtROS as supported by our results.
In conclusion, we propose a model where mtROS impact the TLR-
induced ﬁrst wave of type I IFN responses negatively, whereas aﬀect the
RIG-I-mediated second wave of type I IFN production positively
(Fig. 9). The opposing eﬀect of mtROS on the TLR- and RLR-mediated
signaling pathway reﬂects the versatile role of mtROS in ﬁne-tuning the
type I IFN mediated innate immune responses by pDCs. Further char-
acterization of this spatio-temporal regulation of signaling pathways by
mtROS might expand our knowledge to improve drugs targeting
Fig. 7. Eﬀects of AMA treatments on the ﬁrst and second waves of type I IFN production in primary human pDCs. Freshly isolated primary pDCs were stimulated with the TLR9
agonist CpG-A (1 μM) in the presence or absence of AMA (0.5 μg/ml). After 6 h of stimulation the mRNA expression of IFNA1 was measured by real-time PCR (A) and the level of secreted
IFN-α cytokine was determined by ELISA (B). To investigate the eﬀects of AMA on the second wave of type I IFN responses, primary pDCs were pre-treated with CpG-A for 16 h then after
thorough washing steps cells were re-exposed to 5′ppp-dsRNA (RIGL, 1 μg/ml) in the presence or absence of AMA (0.5 μg/ml). After 3 h the IFNA1 mRNA expression level was determined
by real-time PCR (C) and after 6 h IFN-α protein level was assessed by ELISA (D). Data are presented as means ± SD of three independent experiments. *p < 0.05, **p < 0.01, ***p <
0.001, ****p < 0.0001 vs. control, #p < 0.05 vs. CpG-A or RIGL and ##p < 0.01 vs. CpG-A or RIGL. AMA: Antimycin-A, ND: not determined.
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Fig. 8. Analysis of signaling events in RIG-I-activated GEN2.2 cells in the presence or absence of AMA. Cytosolic RIG-I expression was induced in GEN2.2 by pre-treatment with
CpG-A (0.25 μM) for 16 h then cells were stimulated with the speciﬁc RIG-I ligand 5′ppp-dsRNA (RIGL, 1 μg/ml) in the presence or absence of AMA (0.5 μg/ml). After 2 h of stimulation
the expression of the MAVS adaptor protein (A, B) and after 30 min of stimulation the phosphorylation of IRF3 (C, D) and Akt (E, F) were determined by Western blotting. Representative
blots (A, C, E) and the means ± SD of four independent experiments (B, D, F) are shown. *p < 0.05, **p < 0.01, ***p < 0.001 vs. control, #p < 0.05, ##p < 0.01 vs. RIGL. AMA:
Antimycin-A.
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mtROS-dependent molecules for the treatment of inﬂammatory dis-
eases.
Conﬂict of interest
The authors declare that they have no conﬂict of interest.
Acknowledgements
GEN2.2 cells used in this study were generously provided by Joel
Plumas and Laurence Chaperot of Research and Development
Laboratory, EFS Rhônes-Alpes, 29 Av Maquis du Gresivaudan, BP 35,
38701 La Tronche, France. This work was supported by the National
Research, Development and Innovation Oﬃce (NKFIH, PD 115776 and
PD_16 120887 to K.P.; K 125337 to A.B.), the Romanian Ministry of
Education, Executive Agency for Higher Education, Research,
Development and Innovation Funding (PNCDI II, 119/2014 to A.Sz.,
A.L. and A.B) and the US National Institute of Allergic and Infectious
Diseases (AI062885 to I.B.). The work was also supported by GINOP-
2.3.2-15-2016-00050 project (T.B. and A.B). The project is co-ﬁnanced
by the European Union and the European Regional Development Fund.
K.P. was also supported by the János Bolyai Research Scholarship from
the Hungarian Academy of Sciences.
References
[1] M. Schieber, N.S. Chandel, ROS function in redox signaling and oxidative stress,
Curr. Biol. 24 (10) (2014) R453–R462.
[2] J.F. Turrens, Mitochondrial formation of reactive oxygen species, J. Physiol. 552 (Pt
2) (2003) 335–344.
[3] G.S. Shadel, T.L. Horvath, Mitochondrial ROS signaling in organismal homeostasis,
Cell 163 (3) (2015) 560–569.
[4] X. Li, P. Fang, J. Mai, E.T. Choi, H. Wang, X.F. Yang, Targeting mitochondrial re-
active oxygen species as novel therapy for inﬂammatory diseases and cancers, J.
Hematol. Oncol. 6 (2013) 19.
[5] F.L. Muller, Y. Liu, H. Van Remmen, Complex III releases superoxide to both sides of
the inner mitochondrial membrane, J. Biol. Chem. 279 (47) (2004) 49064–49073.
[6] S.G. Rhee, Y.S. Bae, S.R. Lee, J. Kwon, Hydrogen peroxide: a key messenger that
modulates protein phosphorylation through cysteine oxidation, Sci. Stke. (53)
(2000) (pe1).
[7] T. Finkel, From sulfenylation to sulfhydration: what a thiolate needs to tolerate, Sci.
Signal. 5 (215) (2012) (p. pe10).
[8] M. Pourcelot, D. Arnoult, Mitochondrial dynamics and the innate antiviral immune
response, FEBS J. 281 (17) (2014) 3791–3802.
[9] F.P. Siegal, N. Kadowaki, M. Shodell, P.A. Fitzgerald-Bocarsly, K. Shah, S. Ho,
S. Antonenko, Y.J. Liu, The nature of the principal type 1 interferon-producing cells
in human blood, Science 284 (5421) (1999) 1835–1837.
[10] R. Lande, M. Gilliet, Plasmacytoid dendritic cells: key players in the initiation and
regulation of immune responses, Ann. N. Y Acad. Sci. 1183 (2010) 89–103.
[11] T. Baranek, M. Dalod, How opportunistic agents beneﬁt from viral infections: the
plasmacytoid dendritic cell connection, Cell Host Microbe 4 (4) (2008) 305–307.
[12] Y. Kumagai, H. Kumar, S. Koyama, T. Kawai, O. Takeuchi, S. Akira, Cutting Edge:
TLR-dependent viral recognition along with type I IFN positive feedback signaling
masks the requirement of viral replication for IFN-{alpha} production in plasma-
cytoid dendritic cells, J. Immunol. 182 (7) (2009) 3960–3964.
[13] A. Fullam, M. Schroder, DExD/H-box RNA helicases as mediators of anti-viral in-
nate immunity and essential host factors for viral replication, Biochim. Biophys.
Acta 1829 (8) (2013) 854–865.
[14] A. Szabo, Z. Magyarics, K. Pazmandi, L. Gopcsa, E. Rajnavolgyi, A. Bacsi, TLR li-
gands upregulate RIG-I expression in human plasmacytoid dendritic cells in a type I
IFN-independent manner, Immunol. Cell Biol. 92 (8) (2014) 671–678.
[15] J. Di Domizio, A. Blum, M. Gallagher-Gambarelli, J.P. Molens, L. Chaperot,
J. Plumas, TLR7 stimulation in human plasmacytoid dendritic cells leads to the
induction of early IFN-inducible genes in the absence of type I IFN, Blood 114 (9)
(2009) 1794–1802.
[16] A.E. Dikalova, A.T. Bikineyeva, K. Budzyn, R.R. Nazarewicz, L. McCann, W. Lewis,
D.G. Harrison, S.I. Dikalov, Therapeutic targeting of mitochondrial superoxide in
hypertension, Circ. Res. 107 (1) (2010) 106–116.
[17] N. Kadowaki, S. Ho, S. Antonenko, R.W. Malefyt, R.A. Kastelein, F. Bazan, Y.J. Liu,
Subsets of human dendritic cell precursors express diﬀerent toll-like receptors and
respond to diﬀerent microbial antigens, J. Exp. Med. 194 (6) (2001) 863–869.
[18] M. Kerkmann, L.T. Costa, C. Richter, S. Rothenfusser, J. Battiany, V. Hornung,
J. Johnson, S. Englert, T. Ketterer, W. Heckl, S. Thalhammer, S. Endres,
G. Hartmann, Spontaneous formation of nucleic acid-based nanoparticles is re-
sponsible for high interferon-alpha induction by CpG-A in plasmacytoid dendritic
cells, J. Biol. Chem. 280 (9) (2005) 8086–8093.
[19] P. Hellman, H. Eriksson, Early activation markers of human peripheral dendritic
cells, Hum. Immunol. 68 (5) (2007) 324–333.
[20] M. Bao, Y.J. Liu, Regulation of TLR7/9 signaling in plasmacytoid dendritic cells,
Protein Cell. 4 (1) (2013) 40–52.
[21] S.H. Yeon, M.J. Song, H.R. Kang, J.Y. Lee, Phosphatidylinositol-3-kinase and Akt
are required for RIG-I-mediated anti-viral signalling through cross-talk with IPS-1,
Immunology 144 (2) (2015) 312–320.
[22] A. Nakanishi, Y. Wada, Y. Kitagishi, S. Matsuda, Link between PI3K/AKT/PTEN
pathway and NOX proteinin diseases, Aging Dis. 5 (3) (2014) 203–211.
[23] S. Marchi, C. Giorgi, J.M. Suski, C. Agnoletto, A. Bononi, M. Bonora, E. De Marchi,
S. Missiroli, S. Patergnani, F. Poletti, A. Rimessi, J. Duszynski, M.R. Wieckowski,
P. Pinton, Mitochondria-ros crosstalk in the control of cell death and aging, J. Signal
Transduct. (2012) 329635.
[24] S.E. Weinberg, L.A. Sena, N.S. Chandel, Mitochondria in the regulation of innate
and adaptive immunity, Immunity 42 (3) (2015) 406–417.
[25] T. Koshiba, K. Yasukawa, Y. Yanagi, S. Kawabata, Mitochondrial membrane po-
tential is required for MAVS-mediated antiviral signaling, Sci. Signal. 4 (158)
(2011) (p. ra7).
[26] K.B. Schwarz, Oxidative stress during viral infection: a review, Free Radic. Biol.
Med. 21 (5) (1996) 641–649.
[27] A.V. Ivanov, V.T. Valuev-Elliston, O.N. Ivanova, S.N. Kochetkov, E.S. Starodubova,
B. Bartosch, M.G. Isaguliants, Oxidative stress during HIV infection: mechanisms
and consequences, Oxid. Med Cell Longev. (2016) 8910396.
[28] X. Lin, R. Wang, W. Zou, X. Sun, X. Liu, L. Zhao, S. Wang, M. Jin, The inﬂuenza
virus H5N1 infection can induce ROS production for viral replication and host cell
death in A549 cells modulated by human Cu/Zn superoxide dismutase (SOD1)
overexpression, Viruses 8 (1) (2016).
[29] K. Machida, K.T. Cheng, C.K. Lai, K.S. Jeng, V.M. Sung, M.M. Lai, Hepatitis C virus
triggers mitochondrial permeability transition with production of reactive oxygen
species, leading to DNA damage and STAT3 activation, J. Virol. 80 (14) (2006)
7199–7207.
[30] S.K. Anand, S.K. Tikoo, Viruses as modulators of mitochondrial functions, Adv.
Virol. (2013) 738794.
Fig. 9. Overview of the eﬀects of elevated level of mtROS on
the endosomal TLR-, and cytosolic RIG-I-mediated pDC acti-
vation. Upon infection cells are aﬀected by many various exo-
genous and endogenous stress factors leading to higher re-
spiratory activity of the mitochondria and subsequent increase in
mtROS production in the cells. We found that the elevated level of
mtROS has a negative impact on the ﬁrst wave of type I IFN re-
sponses mediated by endosomal TLRs whereas it has a positive
eﬀect on the second wave of type I IFN production guided by
cytosolic RIG-I receptor in pDCs. Thus, our data indicate opposing
regulatory role of mtROS depending on the receptor-context in
pDCs.
Z. Agod et al. Redox Biology 13 (2017) 633–645
644
[31] T. El-Bacha, A.T. Da Poian, Virus-induced changes in mitochondrial bioenergetics as
potential targets for therapy, Int. J. Biochem. Cell Biol. 45 (1) (2013) 41–46.
[32] Y. Li, D.F. Boehning, T. Qian, V.L. Popov, S.A. Weinman, Hepatitis C virus core
protein increases mitochondrial ROS production by stimulation of Ca2+ uniporter
activity, FASEB J. 21 (10) (2007) 2474–2485.
[33] K.A. McGuire, A.U. Barlan, T.M. Griﬃn, C.M. Wiethoﬀ, Adenovirus type 5 rupture
of lysosomes leads to cathepsin B-dependent mitochondrial stress and production of
reactive oxygen species, J. Virol. 85 (20) (2011) 10806–10813.
[34] A.P. West, I.E. Brodsky, C. Rahner, D.K. Woo, H. Erdjument-Bromage, P. Tempst,
M.C. Walsh, Y. Choi, G.S. Shadel, S. Ghosh, TLR signalling augments macrophage
bactericidal activity through mitochondrial ROS, Nature 472 (7344) (2011)
476–480.
[35] J.C. Hernandez, J. Arteaga, S. Paul, A. Kumar, E. Latz, S. Urcuqui-Inchima, Up-
regulation of TLR2 and TLR4 in dendritic cells in response to HIV type 1 and co-
infection with opportunistic pathogens, AIDS Res. Hum. Retrovir. 27 (10) (2011)
1099–1109.
[36] S. Torres, J.C. Hernandez, D. Giraldo, M. Arboleda, M. Rojas, J.M. Smit, S. Urcuqui-
Inchima, Diﬀerential expression of toll-like receptors in dendritic cells of patients
with dengue during early and late acute phases of the disease, PLoS Negl. Trop. Dis.
7 (2) (2013) e2060.
[37] L. Oliveira-Nascimento, P. Massari, L.M. Wetzler, The role of TLR2 in infection and
immunity, Front. Immunol. 3 (2012) 79.
[38] D. Tang, R. Kang, H.J. Zeh 3rd, M.T. Lotze, High-mobility group box 1, oxidative
stress, and disease, Antioxid. Redox Signal. 14 (7) (2011) 1315–1335.
[39] H. Rauvala, A. Rouhiainen, RAGE as a receptor of HMGB1 (Amphoterin): roles in
health and disease, Curr. Mol. Med. 7 (8) (2007) 725–734.
[40] I.E. Dumitriu, P. Baruah, M.E. Bianchi, A.A. Manfredi, P. Rovere-Querini,
Requirement of HMGB1 and RAGE for the maturation of human plasmacytoid
dendritic cells, Eur. J. Immunol. 35 (7) (2005) 2184–2190.
[41] G. Daﬀu, C.H. del Pozo, K.M. O'Shea, R. Ananthakrishnan, R. Ramasamy,
A.M. Schmidt, Radical roles for RAGE in the pathogenesis of oxidative stress in
cardiovascular diseases and beyond, Int. J. Mol. Sci. 14 (10) (2013) 19891–19910.
[42] K. Pazmandi, Z. Magyarics, I. Boldogh, A. Csillag, E. Rajnavolgyi, A. Bacsi,
Modulatory eﬀects of low-dose hydrogen peroxide on the function of human plas-
macytoid dendritic cells, Free Radic. Biol. Med. 52 (3) (2012) 635–645.
[43] M. Swiecki, M. Colonna, The multifaceted biology of plasmacytoid dendritic cells,
Nat. Rev. Immunol. 15 (8) (2015) 471–485.
[44] T. Koshiba, Mitochondrial-mediated antiviral immunity, Biochim. Biophys. Acta
1833 (1) (2013) 225–232.
[45] M.C. Tal, M. Sasai, H.K. Lee, B. Yordy, G.S. Shadel, A. Iwasaki, Absence of autop-
hagy results in reactive oxygen species-dependent ampliﬁcation of RLR signaling,
Proc. Natl. Acad. Sci. USA 106 (8) (2009) 2770–2775.
[46] R. Gonzalez-Dosal, K.A. Horan, S.R. Paludan, Mitochondria-derived reactive oxygen
species negatively regulates immune innate signaling pathways triggered by a DNA
virus, but not by an RNA virus, Biochem. Biophys. Res. Commun. 418 (4) (2012)
806–810.
[47] B. Feng, C. Ye, L. Qiu, L. Chen, Y. Fu, W. Sun, Mitochondrial ROS release and
subsequent Akt activation potentially mediated the anti-apoptotic eﬀect of a 50-Hz
magnetic ﬁeld on FL cells, Cell. Physiol. Biochem. 38 (6) (2016) 2489–2499.
[48] I.A. Buskiewicz, T. Montgomery, E.C. Yasewicz, S.A. Huber, M.P. Murphy,
R.C. Hartley, R. Kelly, M.K. Crow, A. Perl, R.C. Budd, A. Koenig, Reactive oxygen
species induce virus-independent MAVS oligomerization in systemic lupus er-
ythematosus, Sci. Signal. 9 (456) (2016) (p. ra115).
[49] L. Chaperot, A. Blum, O. Manches, G. Lui, J. Angel, J.P. Molens, J. Plumas, Virus or
TLR agonists induce TRAIL-mediated cytotoxic activity of plasmacytoid dendritic
cells, J. Immunol. 176 (1) (2006) 248–255.
Z. Agod et al. Redox Biology 13 (2017) 633–645
645
